219 / 1631
Cardiovascular disease after therapy for HL:
A detailed analysis of 9 collaborative EORTC-LYSA trials
0
5
10
15
20
25
30
35
40
0
10
20
30
40
50
60
70
80
90
100
Numberof patients at risk:
2811
947
348
108
9
3
0
0
1775
1246
668
304
150
56
26
14
4586
2193
1016
412
159
59
26
14
LSQ responder
LSQ
non-responder
Totalcohort
LSQ responder
LSQ
non-responder
Totalcohort
4120
1919
6039
A
Time since treatment start (years)
Cumulative incidence (%)
50
B
Maraldo et al, Lancet Hemat in 2015
Cumulative incidence curves of first cardiovascular disease by LSQ-responder status and for the
whole cohort (n=6,039)
LSQ responder
LSQ non responder
Total cohort